Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Acute myeloid leukemia (AML) outcomes remain poor despite novel therapies, highlighting an urgent need for improved treatments.
• Differentiation-inducing therapies are successful in acute promyelocytic leukemia but require exploration in other AML subtypes.

Purpose of the Study:

• To identify and characterize novel agents that promote myeloid differentiation across all AML subtypes.
• To investigate the mechanism of action of these agents, focusing on epigenetic modifications.

Main Methods:

• Screening and characterization of lysine deacetylase inhibitors (CM-444 and CM-1758).
• Assessment of myeloid differentiation induction in AML cell lines at low, non-cytotoxic doses.
• Acetylome analysis to identify protein targets and pathways modulated by the inhibitors.

Main Results:

• CM-444 and CM-1758 demonstrated the capacity to induce myeloid differentiation in all tested AML subtypes.
• These inhibitors were effective at low, non-cytotoxic concentrations, distinguishing them from commercial histone deacetylase inhibitors.
• Treatment modulated acetylation of non-histone proteins within the enhancer-promoter regulatory complex, including bromodomain proteins.

Conclusions:

• CM-444 and CM-1758 represent potential differentiation-based therapeutic agents for a broad range of acute myeloid leukemia subtypes.
• The mechanism involves acetylation of key regulatory proteins, enhancing transcription factors essential for differentiation therapy.
• These findings suggest a promising new strategy for treating acute myeloid leukemia.